Linical expands its global coverage through establishing its first affiliate in the Southern Hemisphere
Osaka, Japan (August 1, 2024) – Linical, a global Contract Research Organization (CRO) for full-service drug development, is pleased to announce that it has established a subsidiary in Australia to support the organization’s continued growth and global footprint.
Linical, headquartered in Japan, provides extensive coverage for pharmaceutical and biotechnology clients across Europe, North America, and Asia Pacific. Linical Australia is the Group's first Southern Hemisphere affiliate, enabling the organization to provide CRO services and localized expertise for clinical trials conducted in Australia. Linical has already undertaken several international clinical trials with sites and patients in Australia and continues to see a growing demand for clinical development in the Australian market. Through establishing a physical presence in Australia, the organization can better support future projects in this region and deliver high quality services. Experienced project teams with knowledge of the Australian clinical and regulatory environment will add value to clients’ projects.
“Australia provides many appealing business opportunities, including tax incentives, to pharmaceutical and biotech companies conducting clinical trials in the country, and there is particularly strong demand from U.S. biotech companies,” stated Clareece West, President and CCO of Linical, America and Europe. “Furthermore, there are many instances where sponsors conduct Phase 1 clinical trials in Australia and then conduct large-scale Phase 2 and 3 clinical trials in Europe and the United States to obtain marketing approval, which is expected to lead to large, global projects.
As the globalization and innovation of drug development continues, the importance of a CRO that can provide high-quality services in any region with an extensive understanding of international standards is paramount to success. As a leading clinical development partner trusted by our customers, we strive to deliver new drugs, safely and efficiently, to as many patients as possible across the globe.”
About Linical
Linical is a public, mid-sized Contract Research Organization headquartered in Japan with a significant presence across all major markets including North America, Europe, and Asia-Pacific. Linical provides the full spectrum of drug development services from early stage to large-scale, multinational studies. Our areas of focus include Phase I-IV studies in oncology, neurology & psychiatry, immunology & vaccine, and endocrinology & metabolic diseases.
Media Contact
Alison Cundari
Senior Director, Marketing & Corporate Communications
acundari@linical.com